A share price of Immunovant Inc [IMVT] is currently trading at $27.16, up 1.00%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The IMVT shares have gain 7.69% over the last week, with a monthly amount drifted -9.32%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Oppenheimer reaffirmed its Outperform rating on October 09, 2024, and elevated its price target to $53. On March 28, 2024, Oppenheimer initiated with a Outperform rating and assigned a price target of $50 on the stock. Goldman started tracking the stock assigning a Buy rating and suggested a price target of $50 on March 13, 2024. JP Morgan initiated its recommendation with a Overweight and recommended $51 as its price target on February 20, 2024. Wolfe Research started tracking with a Outperform rating for this stock on February 15, 2024, and assigned it a price target of $55. In a note dated December 12, 2023, Deutsche Bank initiated an Buy rating and provided a target price of $50 on this stock.
Immunovant Inc experienced fluctuations in its stock price throughout the past year between $24.61 and $45.58. Currently, Wall Street analysts expect the stock to reach $42.83 within the next 12 months. Immunovant Inc [NASDAQ: IMVT] shares were valued at $27.16 at the most recent close of the market. An investor can expect a potential return of 57.7% based on the average IMVT price forecast.
Analyzing the IMVT fundamentals
Gross Profit Margin for this corporation currently stands at 0.87% with Operating Profit Margin at -223.82%, Pretax Profit Margin comes in at -215.15%, and Net Profit Margin reading is -215.34%. To continue investigating profitability, this company’s Return on Assets is posted at -0.63, Equity is -0.56 and Total Capital is -0.75.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 26.65 points at the first support level, and at 26.14 for the second support level. However, for the 1st resistance point, the stock is sitting at 27.53, and for the 2nd resistance point, it is at 27.90.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Immunovant Inc [NASDAQ:IMVT] is 7.61. In addition, the Quick Ratio stands at 7.61 and the Cash Ratio stands at 7.1.
Transactions by insiders
Recent insider trading involved Levine Mark S., Chief Legal Officer, that happened on Nov 20 ’24 when 3650.0 shares were sold. Chief Medical Officer, Macias William L. completed a deal on Nov 20 ’24 to sell 3353.0 shares. Meanwhile, Chief Financial Officer Barnett Eva Renee sold 4174.0 shares on Nov 20 ’24.
